We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Case Study · November 24, 2020

Ambulatory Microdose Induction of Buprenorphine–Naloxone in Sickle Cell Disease

Pediatric Blood & Cancer


Additional Info

Pediatric Blood & Cancer
Ambulatory Microdose Induction of Buprenorphine–Naloxone in Two Adolescent Patients With Sickle Cell Disease
Pediatr Blood Cancer 2020 Oct 27;[EPub Ahead of Print], BM Buchheit, T Joslin, HN Turner, TE Wong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading